Cancers, Vol. 10, Pages 445: Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy
Cancers, Vol. 10, Pages 445: Pharmacokinetics of Sublingually Delivered Fentanyl in Head and Neck Cancer Patients Treated with Curatively Aimed Chemo or Bioradiotherapy
Cancers doi: 10.3390/cancers10110445
Authors:
Evelien J. M. Kuip
Wendy H. Oldenmenger
Esther Oomen-de Hoop
Gerda M. Verduijn
Martine F. Thijs-Visser
Peter de Bruijn
Esther van Meerten
Stijn L. W. Koolen
Ron H. J. Mathijssen
Carin C. D. van der Rijt
Over 90% of patients treated for head and neck cancer with curatively aimed chemo or bioradiotherapy will develop painful mucositis and xerostomia. Sublingually delivered fentanyl (SDL) is a rapid acting opioid to treat breakthrough pain. It is unclear how SDL is absorbed by the mucosa of these patients. Therefore, the aim of this study was to investigate the effects of mucositis and xerostomia on the absorption of SDL. Thirteen patients who received chemo or bioradiotherapy (RT), were given a single dose of fentanyl: Before start of RT, 3 and 6 weeks after start of RT, and 6 weeks after finishing RT. Pharmacokinetic samples were taken. The primary endpoint was the relative difference (RD) between systemic exposure to fentanyl (area under the curve; AUC) at baseline (AUCbaseline) and fentanyl AUC in the presence of mucositis grade ≥2. The secondary endpoint was the RD between AUCbaseline and fentanyl AUC in the presence of xerostomia, which were analyzed by means of a paired t-test on log-transformed data. Mucositis resulted in a...
Source: Cancers - Category: Cancer & Oncology Authors: Evelien J. M. Kuip Wendy H. Oldenmenger Esther Oomen-de Hoop Gerda M. Verduijn Martine F. Thijs-Visser Peter de Bruijn Esther van Meerten Stijn L. W. Koolen Ron H. J. Mathijssen Carin C. D. van der Rijt Tags: Article Source Type: research